{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:19:55Z","timestamp":1791836395706,"version":"4.3.4"},"reference-count":32,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2017,1,23]]},"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1136\/ejhpharm-2016-001107","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T20:55:26Z","timestamp":1488574526000},"page":"176-182","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["A retrospective and observational analysis of harmful excipients in medicines for hospitalised neonates in Latvia"],"prefix":"10.1136","volume":"25","author":[{"given":"Inese","family":"Sviestina","sequence":"first","affiliation":[{"name":"University Children\u2019s Hospital, Riga, Latvia"},{"name":"Faculty of Pharmacy, Riga Stradins University, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dzintars","family":"Mozgis","sequence":"additional","affiliation":[{"name":"Department of Public Health and Epidemiology, Riga Stradins University, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,3,3]]},"reference":[{"key":"2025090501305377000_25.4.176.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2014.09.002"},{"key":"2025090501305377000_25.4.176.2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2008.146035"},{"key":"2025090501305377000_25.4.176.3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1542\/peds.77.4.593","article-title":"Polysorbate 80 and E-Ferol toxicity","volume":"77","author":"Alade","year":"1986","journal-title":"Pediatrics"},{"key":"2025090501305377000_25.4.176.4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2008.03323.x","article-title":"Acute amiodarone toxicity due to an administration error: could excipient be responsible?","volume":"67","author":"Masi","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"2025090501305377000_25.4.176.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2011.01.006"},{"key":"2025090501305377000_25.4.176.6","unstructured":"European Medicines Agency. Guideline on pharmaceutical development of medicines for paediatric use. EMA\/CHMP\/QWP\/805880\/2012 Rev 2. 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/07\/WC500147002.pdf (accessed 5 May 2016)."},{"key":"2025090501305377000_25.4.176.7","unstructured":"European Medicines Agency. Guideline on the investigation of medicinal products in the term and preterm neonate. 2009. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003754.pdf (accessed 5 May 2016)."},{"key":"2025090501305377000_25.4.176.8","unstructured":"Rowe RC . Handbook of pharmaceutical excipients. 6th Edition: Pharmaceutical Press, 2009:888."},{"key":"2025090501305377000_25.4.176.9","unstructured":"European Commission. Excipients in the label and package leaflet of medicinal products for human use. 2003. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003412.pdf. (accessed 28 Feb 2016)."},{"key":"2025090501305377000_25.4.176.10","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1542\/peds.74.6.1114","article-title":"E-ferol: what happened and what now?","volume":"74","author":"Phelps","year":"1984","journal-title":"Pediatrics"},{"key":"2025090501305377000_25.4.176.11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1542\/peds.89.1.159","article-title":"Do you remember E-Ferol? the penalty for selling untested drugs in neonatology: fines and a jail sentence","volume":"89","author":"Lucey","year":"1992","journal-title":"Pediatrics"},{"key":"2025090501305377000_25.4.176.12","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2014-307793"},{"key":"2025090501305377000_25.4.176.13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-12-136"},{"key":"2025090501305377000_25.4.176.14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ijpharm.2013.08.078","article-title":"European Study of neonatal Exposure to Excipients: an update","volume":"457","author":"Turner","year":"2013","journal-title":"Int J Pharm"},{"key":"2025090501305377000_25.4.176.15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ijpharm.2015.06.016","article-title":"The STEP database through the end-users eyes--USABILITY STUDY","volume":"492","author":"Salunke","year":"2015","journal-title":"Int J Pharm"},{"key":"2025090501305377000_25.4.176.16","first-page":"1","article-title":"Esnee project: strategy for the extensive review of the literature on excipient toxicities","volume":"19","author":"Vaconsin","year":"2012","journal-title":"EurJ\u00a0Hosp Pharm"},{"key":"2025090501305377000_25.4.176.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2013.11.003"},{"key":"2025090501305377000_25.4.176.18","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2009.160192"},{"key":"2025090501305377000_25.4.176.19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijpharm.2012.05.014","article-title":"The propylene glycol research project to illustrate the feasibility and difficulties to study toxicokinetics in neonates","volume":"435","author":"Kulo","year":"2012","journal-title":"Int J Pharm"},{"key":"2025090501305377000_25.4.176.20","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2010.190330"},{"key":"2025090501305377000_25.4.176.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04312.x"},{"key":"2025090501305377000_25.4.176.22","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0b013e31819a383c"},{"key":"2025090501305377000_25.4.176.23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40272-016-0173-5","article-title":"Product substitution as a way forward in avoiding potentially harmful excipients in neonates","volume":"18","author":"Nellis","year":"2016","journal-title":"Pediatric Drugs"},{"key":"2025090501305377000_25.4.176.24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11096-016-0277-6","article-title":"Harmful excipients in medicines for neonates in Spain","volume":"38","author":"Garcia-Palop","year":"2016","journal-title":"Int J Clin Pharm"},{"key":"2025090501305377000_25.4.176.25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12887-016-0551-8","article-title":"Off-label use and harmful potential of drugs in a NICU in Brazil: A descriptive study","volume":"16","author":"de Souza","year":"2016","journal-title":"BMC Pediatr"},{"key":"2025090501305377000_25.4.176.26","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3109\/14767058.2014.976549","article-title":"The prevalence and pattern of pharmaceutical and excipient exposure in a neonatal unit in Slovenia","volume":"28","author":"Fister","year":"2015","journal-title":"The Journal of Maternal-Fetal & Neonatal Medicine"},{"key":"2025090501305377000_25.4.176.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03982.x"},{"key":"2025090501305377000_25.4.176.28","unstructured":"World Health Organization. Preterm birth. Fact sheet N\u00b0363. http:\/\/www.who.int\/mediacentre\/factsheets\/fs363\/en\/ (accessed 12\u00a0Dec 2015)."},{"key":"2025090501305377000_25.4.176.29","unstructured":"Behrman RE , Butler AS , eds. Preterm birth: causes, consequences, and prevention. Washington DC: National Academies Press, 2007. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK11382\/ (accessed 16 Jun 2016)."},{"key":"2025090501305377000_25.4.176.30","doi-asserted-by":"crossref","unstructured":"Balan S , Hassali MA , Mak VS . Challenges in pediatric drug use: A pharmacist point of view. \u00a0Res Social Adm Pharm\u00a0\u00a0 2016. pii: S1551-7411(6)30201-7.doi:10.1016\/j.sapharm.2016.06.014","DOI":"10.1016\/j.sapharm.2016.06.014"},{"key":"2025090501305377000_25.4.176.31","unstructured":"EMA. Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. 2007 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003382.pdf (accessed 2 Dec 2016)."},{"key":"2025090501305377000_25.4.176.32","unstructured":"Propylene glycol in medicinal products for children. Assessment report. 2014 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2014\/03\/WC500163989.pdf(accessed 2 Dec 2016)."}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2016-001107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T08:31:15Z","timestamp":1757061075000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2016-001107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,3]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,6,28]]},"published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1136\/ejhpharm-2016-001107"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2016-001107","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,3]]}}}